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Introduction
Breast cancer is the most common female cancer. It is
diagnosed in more than a million women worldwide and
accounts for more than 400 000 deaths yearly. More than
110 cases per 100 000 of the population are diagnosed in
Germany and Austria every year.1 The incidence of
breast cancer increases with age, and about three-
quarters of the women affected are postmenopausal. In
these individuals, about 80% of tumours are hormone-
receptor positive.2
For more than 20 years, the anti-oestrogen tamoxifen
has been the established endocrine adjuvant therapy
after surgery for postmenopausal women with early
breast cancer. 5 years is generally judged the optimum
duration for treatment,3 since tamoxifen therapy
beyond 5 years seems to confer no extra beneﬁt in
terms of disease-free survival.4,5 However, several side-
effects are inherent with long-term tamoxifen
treatment. The partial oestrogenic activity of tamoxifen
in some tissues leads to an increased risk of
endometrial cancer and thromboembolic events over
the course of treatment.6–8 Tamoxifen resistance can
also develop.9 The 5-year standard for adjuvant
tamoxifen therapy, therefore, seems to be imposed by
the limitations of the drug rather than by the optimum
duration of therapy. In particular, the relapse pattern
for low-risk and intermediate-risk tumours indicates
that adjuvant treatment should continue after 5 years,
with overview results suggesting that there is a 1·5–2%
yearly risk of recurrence of breast cancer in years 5–15
after initial diagnosis.10,11
The 15-year outcome of some oestrogen-receptor
positive tumours might be worse than that of oestrogen-
receptor negative lesions.12 The administration of
tamoxifen beyond the optimum time of efﬁcacy might,
therefore, result in side-effects without a concomitant
therapeutic beneﬁt.
The limitations of tamoxifen have led to a search for
alternative endocrine therapies with increased efﬁcacy
and fewer long-term complications. The third-
generation aromatase inhibitors anastrozole, letrozole,
and exemestane are highly selective for aromatase and
inhibit 97–99% of oestrogen synthesis from this
source.13,14 Results of trials such as the ATAC study15 have
shown the improved efﬁcacy and tolerability of
anastrozole over tamoxifen, and data now support the
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Summary 
Background Tamoxifen has been the standard adjuvant treatment for postmenopausal women with hormone-
responsive early breast cancer for more than 20 years. However, the third-generation aromatase inhibitor
anastrozole has proven efﬁcacy and tolerability beneﬁts compared with tamoxifen when used as initial adjuvant
therapy. We investigate whether women who have received a period of adjuvant tamoxifen would beneﬁt from being
switched to anastrozole.
Methods We present a combined analysis of data from two prospective, multicentre, randomised, open-label trials
with nearly identical inclusion criteria. Postmenopausal women with hormone-sensitive early breast cancer who had
completed 2 years’ adjuvant oral tamoxifen (20 or 30 mg daily) were randomised to receive 1 mg oral anastrozole
(n=1618) or 20 or 30 mg tamoxifen (n=1606) daily for the remainder of their adjuvant therapy. The primary endpoint
was event-free survival, with an event deﬁned as local or distant metastasis, or contralateral breast cancer. Analysis
was by intention to treat.
Findings 3224 patients were included in analyses. At a median follow-up of 28 months, we noted a 40% decrease in
the risk for an event in the anastrozole group as compared with the tamoxifen group (67 events with anastrozole vs
110 with tamoxifen, hazard ratio 0·60, 95% CI 0·44–0·81, p=0·0009). Both study treatments were well tolerated.
There were signiﬁcantly more fractures (p=0·015) and signiﬁcantly fewer thromboses (p=0·034) in patients treated
with anastrozole than in those on tamoxifen.
Interpretation These data lend support to a switch from tamoxifen to anastrozole in patients who have completed
2 years’ adjuvant tamoxifen. 
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use of 5 years’ anastrozole as adjuvant therapy for
postmenopausal women with early breast cancer.
However, tamoxifen is still a useful and ubiquitous
treatment option, and by employing a strategy of
switching therapy from tamoxifen to an aromatase
inhibitor, the unnecessary longer-term side-effects of
tamoxifen might be obviated and the complications of
long-term tamoxifen therapy avoided. Data indicate a
positive effect on recurrence-free survival when
switching from tamoxifen to an aromatase inhibitor.16,17
The most recent technical assessment from the
American Society of Clinical Oncology (ASCO)18
recommends that optimum adjuvant therapy for
postmenopausal women should now include the use of
an aromatase inhibitor, either as initial treatment or
after 2–5 years’ treatment with tamoxifen, to reduce the
risk of tumour recurrence. The aim of the Austrian
Breast and Colorectal Cancer Study Group (ABCSG)
trial 8/Arimidex-Nolvadex (ARNO) 95 combined
analysis was to assess whether switching to anastrozole
after 2 years’ tamoxifen treatment is more effective than
the standard 5 years’ adjuvant tamoxifen therapy. 
Methods
Patients
This study is a prospectively-planned, event-driven
combined analysis of two trials—ABCSG trial 8 and the
ARNO 95 trial by the German Adjuvant Breast Cancer
Group (GABG)—both of which were prospective,
multicentre, randomised, open-label studies and had
broadly similar inclusion criteria and outcome measures.
Eligible patients were postmenopausal women aged
80 years or younger (ABCSG trial 8) or 75 years or
younger (ARNO 95) with histologically veriﬁed, locally
radically treated invasive or minimally invasive breast
cancer without previous chemotherapy, hormone
therapy, or radiotherapy. Postmenopausal status was
assumed for patients whose last menstruation took place
at least 12 months before study entry, for those who had
undergone bilateral ovariectomy, or for whom follicle-
stimulating hormone and luteinising hormone
concentrations indicated postmenopausal status. All
patients had endocrine-responsive tumours—ie, with
concentrations of oestrogen receptors or progesterone
receptors of more than 10 fmol/mg cytosol protein, or
were oestrogen-receptor or progesterone-receptor
positive as assessed histochemically. ABCSG trial 8
included patients with G1 and G2 ductal carcinoma and
Gx lobular tumours, whereas patients with ductal
carcinoma of any grade were recruited to ARNO 95.
Tumours were graded according to the Bloom and
Richardson scale in both studies.19
Inclusion criteria common to both trials were absence
of preoperative chemotherapy, hormone therapy, or
radiotherapy, tumour inﬁltration of up to ten (ABCSG
trial 8) or nine (ARNO 95) lymph nodes, and absence of
organ metastases. Exclusion criteria across both trials
were indeterminate menopausal status (or menopausal
status maintained by medication), presence of secondary
malignant disease, tumour inﬁltration of skin or breast
muscle (T4 tumours), and presence of other
concomitant serious medical conditions—eg, those
involving bone marrow function, the central nervous
system, uncompensated cardiac insufﬁciency, or
uncontrolled local or systemic infection. Although
hormone replacement therapy was not excluded in the
procotol, it was considered as explicitly contraindicated
in both countries for patients receiving adjuvant breast
cancer treatment.
Eligible patients underwent modiﬁed radical
mastectomy or breast-conserving surgery with axiliary
lymph-node dissection or sentinel lymph-node biopsy
(with or without subsequent radiotherapy), followed by
adjuvant tamoxifen therapy started within 6 weeks
(ABCSG trial 8) or 4 weeks (ARNO 95) of surgery or
radiotherapy, where applicable. 
For both studies, patients had to complete 2 years’
adjuvant oral tamoxifen therapy in accordance with local
guidelines (20 mg daily for ABCSG trial 8, and 20 mg or
30 mg daily for ARNO 95; patients administered 30 mg
continued on that dose unless otherwise indicated).
Women were randomised before beginning treatment
with tamoxifen in ABCSG trial 8 and within 2 years of
tamoxifen treatment in ARNO 95. The accrual period for
this combined analysis was January, 1996, to August,
2003. Since the randomisation processes in Austria and
Germany differed, the timepoint of 2 years post-surgery
was used as a starting point for this analysis.
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3901 patients randomised in ABCSG trial 8
            First 2 years of tamoxifen treatment
            were part of the study
            Randomisation was done immediately
            after surgery
   164 patients ineligible
1475 excluded after randomisation and
            not included in combined analysis
       23 non-breast-cancer-related deaths
       53 events
       44 secondary carcinomas
     275 treatment discontinuations for other
              reasons in first 2 years after surgery
  1080 not yet completed 2-year tamoxifen
              pretreatment before receipt of
              randomised medication
2262 eligible for combined analysis
3224 included in combined analysis
     21 patients ineligible
     76 excluded after randomisation and
            not included in combined analysis
          3 non-breast-cancer-related deaths
          9 events
          5 secondary carcinomas
        49 treatment discontinuations in first
              2 years after surgery
        10 last follow-up date within 2 years of 
              surgery
1059 patients randomised in ARNO 95
            First 2 years of tamoxifen treatment
            were not part of the study
            Randomisation was done at any time
            within 2 years after surgery
   962 eligible for combined analysis
1606 assigned tamoxifen and assessed
            for primary endpoint
1618 assigned anastrozole and assessed
            for primary endpoint
Figure 1: Trial proﬁle
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All patients provided written informed consent and
both studies were done in accordance with the
Declaration of Helsinki. ABCSG trial 8 and ARNO 95
were approved by the relevant ethics committees in
Austria and Germany, respectively. 
Procedures
Randomisation for ABCSG trial 8 was done centrally at
the ABCSG randomisation centre, Vienna, Austria.
Randomisation for ARNO 95 was done at the
Department of Medical Biometry and Statistics,
Freiburg, Germany. The computer-assisted randomi-
sation schedules for ABCSG trial 8 were based on
minimisation as a dynamic algorithm designed to
counteract imbalance between treatments, taking
stratiﬁcation factors into account. For ARNO 95, these
schedules were based on block randomisation. Patients
were randomised to either continue tamoxifen or to
switch to oral anastrozole (1 mg per day) for 3 years after
completion of 2 years’ adjuvant therapy. In Austria, this
randomisation was done within 6 weeks after surgery,
whereas in Germany it was done at any time between
surgery and 6 weeks after completion of the ﬁrst 2 years’
adjuvant therapy.
Patients received a physical examination and were
monitored for safety and tolerability. Case report forms
were provided for documentation and adhered to as per
protocol. In Austria, the monitoring took place at
3-monthly intervals throughout the ﬁrst year of
randomised therapy, at 6-monthly intervals in the
second and third year, and yearly thereafter. In
Germany, assessment of patients was done at 6-monthly
intervals. There were no observation-free intervals.
Gynaecological examinations, thoracic X-rays, skeletal
scintigraphy, and abdominal sonography, liver
ultrasound, and standard mammography were done as
appropriate (at least yearly) to identify the presence of
disease recurrence (locoregional, contralateral, or distant
metastatic tumour [lymph node or organ]). The
assessments done at each visit were common to, and the
number of patients with data was similar in, both
treatment groups. Events were conﬁrmed histologically,
cytologically, or, where not clinically obvious, by the
various radiological screening methods used at the
regular assessments.
The primary endpoint was event-free survival, deﬁned
as time to relapse at any site or incidence of contralateral
breast cancer. Distant recurrence-free survival and
tolerability issues were also compared.
Statistical analysis 
In Austria, patients were allocated to the treatment
groups according to the method of Pocock and Simon,20
stratifying for the following prognostic factors: age,
tumour grade, tumour stage, nodal status, and
participating centres grouped into federal states. In
Germany, only the participating centre was considered
during randomisation. For the common analysis, we
calculated that 278 events would be required for the
ﬁnal analysis to detect a hazard ratio (HR) of 0·7 for
event-free survival between the treatment groups with a
power of 80% and a two-sided signiﬁcance level of
0·05. Interim analyses were planned on reaching 139
and 209 events, using a signiﬁcance level of 0·001
(stopping boundary) to maintain a signiﬁcance level of
0·05 for the ﬁnal analysis. The number of events
needed to trigger the ﬁrst interim analysis was reached
in April, 2004 (143 observed events). The Steering
Committee decided to reassess all data for accuracy. As
the stopping boundary for event-free survival was
reached at this analysis, the independent data
monitoring committee decided, in November, 2004, to
recommend close of recruitment and to publish the
combined analysis data.
Analyses were by intention to treat. Data are presented
in Kaplan-Meier curves,21 and tested by log-rank tests.22,23
HRs and their corresponding 95% CIs were estimated
by the proportional-hazards regression model of Cox.24
Main analyses were based on the ﬁrst corresponding
event per patient. In additional sensitivity analyses, ﬁrst
events only were considered. Thus, for analysis of
distant recurrence-free survival, the ﬁrst observed
distant metastasis was included in the main analysis. In
the sensitivity analysis, however, patients who did not
have a distant metastasis as ﬁrst cancer-related event—
eg, secondary cancer, locoregional event, or contralateral
event—were censored at the ﬁrst observed event.
All analyses were done with SAS (version 8.02).
Adverse events were only counted once per patient, and
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Tamoxifen (n=1606) Anastrozole (n=1618)
Age at surgery (years; median, range) 62·0 (41·4–80·0) 62·3 (46·0–80·3)
Affected nodes
None 1188 (74%) 1201 (74%)
1–3 358 (22%) 346 (21%)
4–9 59 (4%) 70 (4%)
Unknown 1 (1%) 1 (1%)
Tumour size
T1 1119 (70%) 1136 (70%)
T2 464 (29%) 463 (29%)
T3 21 (1%) 18 (1%)
Unknown 2 (1%) 1 (1%)
Tumour grade 
G1, G2, Gx 1504 (94%) 1540 (95%)
G3 91 (6%) 76 (5%)
Unknown 11 (1%) 2 (1%) 
Surgery
Breast-conserving surgery 1242 (77%) 1236 (76%)
Radical modiﬁed mastectomy 362 (23%) 382 (24%)
Unknown 2 (1%) 0 
Hormone receptor status
ER-positive/PgR-positive 1247 (78%) 1272 (79%)
ER-positive/PgR-negative 281 (18%) 283 (18%)
ER-negative/PgR-positive 39 (2%) 28 (2%)
Unknown 39 (2%) 35 (2%)
Data are number (%) unless otherwise indicated. ER=oestrogen receptor; PgR=progesterone receptor.
Table 1: Baseline characteristics
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are described with absolute frequencies and proportions.
Differences in the adverse event rates were estimated
with exact odds ratios (OR) and corresponding 95% CIs.
Exact ORs stratiﬁed by country were calculated for the
ﬁve types of serious adverse events available for Austrian
and German patients (myocardial infarct, embolism,
thromboses, fractures, and endometrial cancer). The
exact calculations were done with StatXact (version 6).
All p values are two-sided, and a p less than 0·05 was
judged signiﬁcant.
Role of the funding source
The study designs were developed by the ABCSG and
the GABG. The management of the trial has been
undertaken by the ABCSG and GABG with funding and
organisational support from the trial sponsors:
AstraZeneca in Austria and the GABG in Germany. The
ABCSG statistician analysed all data. AstraZeneca
funded editorial assistance in the form of technical
preparation of references, ﬁgures, tables, technical
editing for English language, formatting of the report to
Lancet style, and administrative support. AstraZeneca
had no role in data interpretation. The corresponding
author had full access to all the data in the study and had
ﬁnal responsibility for the decision to submit for
publication.
Results
Figure 1 shows the trial proﬁle. 3224 patients (2262 in
ABCSG trial 8 and 962 in ARNO 95) were randomised
to either continue tamoxifen (n=1606) or switch to
anastrozole (n=1618). Median follow-up was 28 months
(95% CI 26–30) after initial treatment with tamoxifen.
The treatment groups were well balanced in terms of
age, nodal status, tumour stage, tumour grade,
oestrogen-receptor and progesterone-receptor status,
and previous surgery (table 1). At the time of disclosure
of trial data, 882 (55%) patients assigned anastrozole
and 884 (55%) assigned tamoxifen had completed
5 years of treatment.
Event-free survival was higher in patients who took
anastrozole than in those who continued treatment with
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15
10
5
0
0 1 2 3
Time (years)
p=0·0009
HR 0·60 (95% CI 0·44–0·81)
4 5
Numbers at risk (estimated proportion of events)
Tamoxifen
Anastrozole
1217 (2·5%)
1243 (1·4%)
858 (5·4%)
874 (2·9%)
593 (7·3%)
623 (4·3%)
343 (9·4%)
375 (5·2%)
176 (13·2%)
178 (9·7%)
Tamoxifen
Anastrozole
All patients (n=3224)
Receptor (ER/PgR)
  Positive/positive (n=2519)
  Positive/negative (n=564)
Nodal status
  Negative (n=2389)
  Positive (n=833)
Grading
  G1, G2, GX (n=3044)
  G3 (n=167)
0·58 (0·41–0·81)
0·93 (0·44–1·96)
0·63 (0·40–1·00)
0·58 (0·39–0·87)
0·66 (0·46–0·93)
0·42 (0·19–0·92)
0·54 (0·35–0·84)
0·67 (0·44–1·02)
0·60 (0·44–0·81)
0·0012
0·8481
0·0506
0·0077
0·0171
0·0295
0·0065
0·0609
0·0009
Age
  60 years (n=1265)
  60 years (n=1959)
0·25 0·50 0·80 1·00
In favour of tamoxifen
1·25 1·50 2·00 3·00
HR (anastrozole vs tamoxifen)
In favour of anastrozole
HR (95% CI) P
Figure 2: Kaplan-Meier curves of event-free survival 
0 timepoint=2 years after surgery. SD at 3 years: tamoxifen=0·81,
anastrozole=0·65
Figure 3: HR (95%CI) for anastrozole versus tamoxifen stratiﬁed by nodal status, tumour grade, age, and hormone receptor status 
ER=oestrogen receptor; PgR=progesterone receptor.
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tamoxifen (ﬁgure 2). 67 events were noted in the
anastrozole group and 110 events in the tamoxifen
group. In the combined analysis, there was an HR of
0·60 (95% CI 0·44–0·81, p=0·0009) in favour of
anastrozole at 3 years post-switch for the occurrence of
an event. With respect to ﬁrst events only, the HR was
0·59 (0·44–0·81, p=0·0008). Event-free survival 3 years
after switching was 92·7% (SD 0·81) for the tamoxifen
group and 95·8% (0·65) for the group switched to
anastrozole, corresponding to an absolute beneﬁt at
3 years of 3·1% (ﬁgure 2).
Figure 3 shows the risk of recurrence of cancer
stratiﬁed by nodal status, tumour grading, age, and
receptor status. Although the 95% CIs of the subgroups
overlap, and so the differences are not signiﬁcant, the
data suggest that women with G1, G2, and Gx lobular
tumours responded better to anastrozole than to
tamoxifen than did those with G3 tumours. For all
patients, irrespective of tumour grading, the advantage
of switching to anastrozole over continuing with
tamoxifen was not affected by nodal status, age at
surgery, or receptor positivity, although there is a (non-
signiﬁcant) suggestion that the beneﬁt of anastrozole in
oestrogen-receptor positive, progesterone-receptor
negative patients is greater (ﬁgure 3). 
In women in whom disease progressed, distant
metastases accounted for 62% (n=110) of recurrences
(ﬁgure 4). Metastases arose in 3% of anastrozole-treated
patients and in 5% of patients treated only with
tamoxifen (HR 0·61, 0·42–0·87, p=0·0067), indicating
a 39% decrease in risk of metastases for women
switching to anastrozole. When looking at distant
metastases as ﬁrst events only, the univariate model
gives an HR of 0·54 (0·37–0·80, p=0·0016).
Contralateral or ipsilateral recurrence accounted for
only 16% (n=28) and 23% (n=41) of recurrences,
respectively. More recurrences were observed in the
tamoxifen group than in the anastrozole group (table 2).
59 individuals in the tamoxifen group and 45 in the
anastrozole group died (table 2).
Overall survival at 3 years post-switch was slightly
higher in patients who switched to anastrozole (97%)
than in those who continued on tamoxifen (96%),
though this difference was not signiﬁcant (p=0·16;
table 2). 
Table 3 shows the incidence of serious adverse events
by treatment group. There were signiﬁcantly more
fractures (p=0·015) and signiﬁcantly fewer thromboses
(p=0·034) in patients treated with anastrozole than in
those treated with tamoxifen. There was also a trend
towards fewer emboli (p=0·064) and endometrial
cancers (p=0·069) in patients treated with anastrozole.
The incidence of predeﬁned adverse events in ABCSG
trial 8 is shown in table 4. No adverse events were
prespeciﬁed in the study protocol of ARNO 95. There
were signiﬁcantly more reports of nausea (p=0·0162)
and a trend towards more reports of bone pain
(p=0·0546) in the anastrozole group than in the
tamoxifen group.
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Time (years)
p=0·0067
HR 0·61 (95% CI 0·42–0·87)
4 5
Numbers at risk (estimated proportion of distant recurrences)
Tamoxifen
Anastrozole
1224 (1·8%)
1247 (1·1%)
869 (4·1%)
879 (2·2%)
600 (6·1%)
631 (2·9%)
351 (6·7%)
382 (3·3%)
181 (8·3%)
181 (6·3%)
Tamoxifen
Anastrozole
Figure 4: Kaplan-Meier curves of distant recurrence-free survival 
0 timepoint=2 years after surgery. SD at 3 years: tamoxifen=0·76,
anastrozole=0·52.
Tamoxifen Anastrozole Total
Total number of events 110 (2) 67 (2) 177 (4)
Locoregional events 24 (0) 20 (3) 44 (3)
Distant metastasis events 75 (4) 46 (7) 121 (11)
Contralateral events 16 (0) 12 (0) 28 (0)
Deaths
Breast cancer-related 31 24 55
Non breast cancer-related 28 21 49
Number of patients who had had a previous event of a different type is given in
parentheses.
Table 2: Recurrences and deaths by treatment group
Tamoxifen (n=1597) Anastrozole (n=1602) OR (95% CI), p
Myocardial infarction 2 (1%) 3 (1%) 1·50 (0·17–17·9), 1·0
Embolism 9 (1%) 2 (1%) 0·22 (0·02–1·07), 0·064
Thromboses 12 (1%) 3 (1%) 0·25 (0·04–0·92), 0·034
Fractures 16 (1%) 34 (2%) 2·14 (1·14–4·17), 0·015
Endometrial cancer 7 (1%) 1 (1%) 1·14 (0·003–1·11), 0·069
Data are number (%) unless otherwise indicated.
Table 3: Serious adverse events by treatment group 
Tamoxifen Anastrozole OR 
(n=1117) (n=1120) (95% CI), p
Hot ﬂushes 560 (50%) 537 (48%) 0·92 (0·77–1·09), 0·3209
Asthenia, somnolence 29 (3%) 37 (3%) 1·28 (0·76–2·18), 0·3880
Allergy, cutaneous toxicity, skin rash 16 (1%) 26 (2%) 1·63 (0·84–3·28), 0·1628
Hair loss 24 (2%) 35 (3%) 1·47 (0·84–2·60), 0·1901
Diarrhoea 9 (1%) 15 (1%) 1·67 (0·68–4·35), 0·3080
Nausea 10 (1%) 25 (2%) 2·53 (1·17–5·92), 0·0162
Vaginal bleeding/discharge 195 (17%) 198 (18%) 1·02 (0·81–1·27), 0·9348
Bone pain 177 (16%) 213 (19%) 1·25 (1·00–1·56), 0·0546
Data are number (%) unless otherwise indicated.
Table 4: Predeﬁned adverse events by treatment group in ABCSG trial 8
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Discussion
Our data show that, in postmenopausal women with
early breast cancer, switching to anastrozole after
2 years’ tamoxifen treatment results in reduced rates of
disease recurrence, particularly with respect to distant
metastases. There are two possible explanations for this
ﬁnding: tamoxifen resistance might be overcome by a
change in treatment; or aromatase inhibitors might
simply be a better treatment option, since they reduce
peripheral oestrogen concentrations to extremely low
levels, whereas tamoxifen is a partial agonist.
The number of women in the combined analysis who
had G3 tumours was small, yet nearly a third of
recurrences arose in this group. Overall, patients with
G1, G2, or Gx lobular tumours responded better to
adjuvant therapy than did those with G3 tumours, as
expected. Undifferentiated tumours generally have a less
pronounced response to endocrine therapy and could,
therefore, be expected to progress more readily; the
5-year survival rate of patients with undifferentiated
tumours at diagnosis is about 20% lower than that of
patients with highly-differentiated or moderately-
differentiated tumours.25 In recognition of this
difference in response, patients with undifferentiated
tumours would be less likely to receive adjuvant
endocrine treatment alone.
Since ABCSG trial 8 and ARNO 95 enrolled
populations with a good prognosis (about three-quarters
of patients were node-negative and a similar proportion
received breast conservation surgery), we did not expect
to see a survival difference at this stage. Furthermore,
longer follow-up is needed to show a signiﬁcant
difference in overall survival in a trial between two
active treatments than in a trial of an active treatment
versus placebo.
The contrasting safety proﬁles of anastrozole and
tamoxifen are well known. We noted signiﬁcantly more
fractures and signiﬁcantly fewer thromboses in patients
treated with anastrozole than in those who received only
tamoxifen. However, we also noted a non-signiﬁcant
tendency towards fewer emboli and endometrial
cancers in women on anastrozole. The ATAC trial15 has
already provided evidence of the long-term safety and
tolerability of anastrozole treatment, and no new safety
concerns arose during this analysis. As expected, the
fracture rate in the group switched to anastrozole was
higher than in the group who received continuous
tamoxifen. However, the fracture rate in the anastrozole
group was lower than that seen at a similar point in the
anastrozole group of the ATAC trial.26 This ﬁnding
could suggest a continued protective effect of tamoxifen
on bone in the ABCSG trial 8/ARNO 95 patients;
anastrozole-treated patients in the ATAC trial had
received no previous treatment with tamoxifen.
However, data from another aromatase inhibitor,
exemestane, do not support this hypothesis, since
patients switched to exemestane after 2–3 years’
tamoxifen17 were more likely than patients who
continued on tamoxifen to have arthralgia and
osteoporosis at a follow-up of 30·6 months. Results
from a bone substudy of that trial showed that after
1 year, exemestane was associated with signiﬁcantly
greater reductions in the lumbar spine and total hip
bone-mineral density (BMD) than tamoxifen. The
decrease in BMD was rapid—within 6 months of
switching to exemestane—and by the end of the ﬁrst
year, the BMD loss was similar to that seen with other
aromatase inhibitors.27
In a placebo-controlled trial28 of the effect of
exemestane on BMD in postmenopausal women with
early breast cancer, the aromatase inhibitor modestly
increased bone loss from the femoral neck.
Management of the increased risk of fractures caused by
BMD loss includes regular BMD screening. For patients
with concomitant risk factors for developing
osteoporosis—eg, advanced age, smoking status, family
history, and high body-mass index—the administration
of bisphosphonates could be considered as a
prophylactic measure. 
Overall, the published work indicates that there are
potential beneﬁts to switching from tamoxifen to an
aromatase inhibitor after 2 years, and that patients could
beneﬁt from the antitumour effects of tamoxifen in the
short term while avoiding the complications of long-
term tamoxifen therapy. However, to date, the studies
have been structured such that the analyses relate only to
the period of switched treatment. Patients in whom
cancer recurs at an early stage or who do not survive to
the end of the initial tamoxifen phase are, therefore,
excluded, and the randomised population is selected
from patients with tumours that show a good response
to endocrine therapy. As such, the results of this
investigation and other switching trials apply only to
those women who have successfully completed
2–3 years’ adjuvant therapy for early breast cancer. They
are not applicable to newly diagnosed patients, and
should not be used to support a treatment strategy of
starting with tamoxifen with the intention of changing to
an aromatase inhibitor after 2 or more years. Overall,
however, the results of these studies show the efﬁcacy
advantages attached to treatment with an aromatase
inhibitor, despite the qualitative differences cross-trial
comparisons reveal as to the magnitude of such
advantages, deﬁnitions of predeﬁned adverse events, or
demography of patients.
The beneﬁts of reduced recurrence of cancer when
switching adjuvant therapy to an aromatase inhibitor
before progression on tamoxifen might be related to
cellular changes within the tumour in response to
tamoxifen treatment. The effect of switching from one
endocrine treatment to another after less than 2 years
needs further investigation, as does switching from
primary therapy with an aromatase inhibitor to other
treatment modalities. Although even less thoroughly
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understood than tamoxifen resistance, resistance to
aromatase inhibitors over 5 years of exposure also leads
to the recurrence of the original disease.29
Switching treatment to an aromatase inhibitor offers
the opportunity to continue adjuvant therapy for longer
than 5 years, since problems of tolerability that arise
from the partial agonist effects of tamoxifen are
circumvented. In one study,30 extended adjuvant therapy
with letrozole, another non-steroidal aromatase
inhibitor, conferred a signiﬁcant beneﬁt in terms of
disease-free survival after 5 years’ tamoxifen therapy.
The extended adjuvant approach is also being
investigated with 3 years’ anastrozole therapy (compared
with no treatment) after the standard 5 years’ treatment
with tamoxifen in ABCSG trial 6A.31
Research indicates that 5 years of treatment with
tamoxifen is no longer the optimum therapy for
postmenopausal women with endocrine-responsive
early breast cancer. The results of the ATAC trial15 show
that 5 years of anastrozole as initial endocrine therapy is
better than tamoxifen for adjuvant monotherapy, and
several trials support changing adjuvant therapy to an
aromatase inhibitor after initial treatment with
tamoxifen. Both of these ﬁndings are taken into account
in the ASCO technology assessment.18 Although further
investigation of the use of aromatase inhibitors is
necessary to ascertain the ideal sequence and duration of
adjuvant endocrine therapy, this combined analysis
conﬁrms that postmenopausal women who receive
tamoxifen as adjuvant therapy should be switched to
anastrozole after 2 years of treatment.
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